New Treatment Breakthrough: Amivantamab Plus Lazertinib for Advanced Lung Cancer – Timothy A. McCarthy, MD
A groundbreaking study published in June 2024 in The New England Journal of Medicine has introduced a promising new treatment for a specific type of advanced lung cancer. The research, co-authored by Alex Spira, MD, PhD, FACP, FACSO, Medical Oncologist and Co-Director of The Virginia Cancer Specialists Research Institute, highlights the combination of two drugs, […]
Enhancing Lung Cancer Treatment: The Promise of Perioperative Immunotherapy – Samantha DiBenedetto, MD
Introduction: Lung cancer remains one of the most challenging and life-threatening diseases; however, several exciting treatment advances show promising benefits. A recent study in which Virginia Cancer Specialists participated under the research leadership of Dr. Alex Spira, the AEGEAN trial, was published in the New England Journal of Medicine (NEJM) earlier this month and has shed light […]
November is Lung Cancer Awareness Month – Advancements in Lung Cancer Treatment
November is Lung Cancer Awareness Month. In recent years, lung cancer treatment has taken incredible steps forward, thanks to breakthrough research and early detection. Here are some of the latest advancements in treating lung cancer. Your browser does not support the video tag.
New Advances in Early-Stage Lung Cancer Treatment – Samantha DiBenedetto, MD
Lung cancer poses a significant healthcare challenge in the United States, with approximately 237,000 individuals newly diagnosed each year. Although the majority of cases are found at an advanced stage, approximately 25-35% of cases are detected early where surgery and chemotherapy can be effective treatment options. Despite these efforts, disease recurrence rates remain high, impacting […]
Landmark Non-Small Cell Lung Cancer Study – Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP
Virginia Cancer Specialists Research Institute – Landmark “Non-Small Cell Lung Cancer Study” – Alexander I. Spira, MD, PhD, FACP Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib – See the […]